Published in Cancer Res on July 15, 2004
Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov (2010) 4.66
Drug development from marine natural products. Nat Rev Drug Discov (2008) 4.08
Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov (2009) 3.20
Synergistic antimicrotubule therapy for prostate cancer. Biochem Pharmacol (2010) 1.44
Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies. J Med Chem (2012) 1.17
Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice. Clin Cancer Res (2006) 1.09
(+)-Discodermolide: Total Synthesis, Construction of Novel Analogues, and Biological Evaluation. Tetrahedron (2007) 1.07
HIV-1 Tat protein enhances microtubule polymerization. Retrovirology (2005) 1.06
Taccalonolide binding to tubulin imparts microtubule stability and potent in vivo activity. Cancer Res (2013) 0.98
New insights into mechanisms of resistance to microtubule inhibitors. Biochim Biophys Acta (2011) 0.96
Distinct pose of discodermolide in taxol binding pocket drives a complementary mode of microtubule stabilization. Biochemistry (2009) 0.94
Microtubule-stabilizing drugs from marine sponges: focus on peloruside A and zampanolide. Mar Drugs (2010) 0.93
Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies. Curr Top Med Chem (2011) 0.89
The Lithistida: important sources of compounds useful in biomedical research. Curr Opin Biotechnol (2010) 0.84
Taxol crystals can masquerade as stabilized microtubules. PLoS One (2008) 0.84
A distinctive structural twist in the aminoimidazole alkaloids from a calcareous marine sponge: isolation and characterization of leucosolenamines A and B. J Nat Prod (2007) 0.83
Total synthesis and biological evaluation of a series of macrocyclic hybrids and analogues of the antimitotic natural products dictyostatin, discodermolide, and taxol. Chem Asian J (2010) 0.83
Peloruside A inhibits microtubule dynamics in a breast cancer cell line MCF7. Invest New Drugs (2010) 0.82
Colchitaxel, a coupled compound made from microtubule inhibitors colchicine and paclitaxel. Beilstein J Org Chem (2006) 0.81
Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice. BMC Cancer (2013) 0.81
Partial depletion of gamma-actin suppresses microtubule dynamics. Cytoskeleton (Hoboken) (2013) 0.80
Design and synthesis of (+)-discodermolide-paclitaxel hybrids leading to enhanced biological activity. J Med Chem (2011) 0.79
Anti-migratory effect of vinflunine in endothelial and glioblastoma cells is associated with changes in EB1 C-terminal detyrosinated/tyrosinated status. PLoS One (2013) 0.78
Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment. Am J Cancer Res (2016) 0.76
Iron complexation to oxygen rich marine natural products: a computational study. Mar Drugs (2010) 0.75
Microtubule-stabilizing properties of the avocado-derived toxins (+)-(R)-persin and (+)-(R)-tetrahydropersin in cancer cells and activity of related synthetic analogs. Invest New Drugs (2016) 0.75
Structural Basis of Microtubule Stabilization by Discodermolide. Chembiochem (2017) 0.75
Microtubules as a target for anticancer drugs. Nat Rev Cancer (2004) 13.93
Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov (2010) 4.66
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol (2007) 3.23
Mechanisms of Taxol resistance related to microtubules. Oncogene (2003) 3.16
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther (2005) 2.70
Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry (2010) 2.07
Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease. Proc Natl Acad Sci U S A (2003) 2.06
How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets (2007) 2.05
Insights into the mechanism of microtubule stabilization by Taxol. Proc Natl Acad Sci U S A (2006) 1.96
Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J Biol Chem (2002) 1.80
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther (2008) 1.78
Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res (2002) 1.71
BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem (2005) 1.61
The interaction between mitotic checkpoint proteins, CENP-E and BubR1, is diminished in epothilone B-resistant A549 cells. Cell Cycle (2010) 1.57
Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res (2003) 1.55
Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res (2007) 1.55
Inhibition of DNA decatenation, but not DNA damage, arrests cells at metaphase. Mol Cell (2004) 1.54
Suppression of microtubule dynamic instability by the +TIP protein EB1 and its modulation by the CAP-Gly domain of p150glued. Biochemistry (2007) 1.48
Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma. PLoS One (2013) 1.48
Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J Biol Chem (2002) 1.44
Higher-order assembly of microtubules by counterions: from hexagonal bundles to living necklaces. Proc Natl Acad Sci U S A (2004) 1.39
Minimal analytical characterization of engineered nanomaterials needed for hazard assessment in biological matrices. Nanotoxicology (2010) 1.38
Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res (2003) 1.36
Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res (2005) 1.34
Modulation of microtubule dynamics by tau in living cells: implications for development and neurodegeneration. Mol Biol Cell (2004) 1.34
Synchrotron X-ray diffraction study of microtubules buckling and bundling under osmotic stress: a probe of interprotofilament interactions. Phys Rev Lett (2004) 1.32
Thermodynamics of heme binding to the HasA(SM) hemophore: effect of mutations at three key residues for heme uptake. Biochemistry (2003) 1.30
Myc stimulates B lymphocyte differentiation and amplifies calcium signaling. J Cell Biol (2007) 1.29
Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res (2004) 1.27
Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther (2009) 1.26
Memo-RhoA-mDia1 signaling controls microtubules, the actin network, and adhesion site formation in migrating cells. J Cell Biol (2008) 1.25
Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther (2004) 1.24
Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res (2006) 1.24
Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther (2010) 1.23
Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr Cancer Drug Targets (2007) 1.23
Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res (2005) 1.22
Low concentrations of taxol cause mitotic delay followed by premature dissociation of p55CDC from Mad2 and BubR1 and abrogation of the spindle checkpoint, leading to aneuploidy. Cell Cycle (2005) 1.22
Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. Biochemistry (2003) 1.22
Direct Costs of Acute Recurrent and Chronic Pancreatitis in Children in the INSPPIRE Registry. J Pediatr Gastroenterol Nutr (2016) 1.20
DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5'-methyl group of the noviose. Biochemistry (2002) 1.20
Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death. Biochim Biophys Acta (2005) 1.19
The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence. Cell Cycle (2005) 1.19
Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther (2010) 1.19
Regulation of microtubule dynamic instability in vitro by differentially phosphorylated stathmin. J Biol Chem (2009) 1.18
Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology (2013) 1.18
Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain. J Biol Chem (2002) 1.17
Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res (2003) 1.17
Three- and four-repeat tau regulate the dynamic instability of two distinct microtubule subpopulations in qualitatively different manners. Implications for neurodegeneration. J Biol Chem (2005) 1.17
Symptom management with massage and acupuncture in postoperative cancer patients: a randomized controlled trial. J Pain Symptom Manage (2007) 1.16
Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther (2010) 1.16
Suppression of centromere dynamics by Taxol in living osteosarcoma cells. Cancer Res (2003) 1.15
MCAK, a Kin I kinesin, increases the catastrophe frequency of steady-state HeLa cell microtubules in an ATP-dependent manner in vitro. FEBS Lett (2004) 1.15
Alpha2beta1-integrin signaling by itself controls G1/S transition in a human adenocarcinoma cell line (Caco-2): implication of NADPH oxidase-dependent production of ROS. Exp Cell Res (2003) 1.14
Cationic liposome-microtubule complexes: pathways to the formation of two-state lipid-protein nanotubes with open or closed ends. Proc Natl Acad Sci U S A (2005) 1.14
The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis. J Biol Chem (2004) 1.13
Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth. Cancer Res (2012) 1.12
Kinetic suppression of microtubule dynamic instability by griseofulvin: implications for its possible use in the treatment of cancer. Proc Natl Acad Sci U S A (2005) 1.11
Dicoumarol: a unique microtubule stabilizing natural product that is synergistic with Taxol. Cancer Res (2003) 1.10
Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res (2002) 1.10
Tubulin proteomics: towards breaking the code. Anal Biochem (2008) 1.10
Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice. Clin Cancer Res (2006) 1.09
Microtubule-targeting agents in angiogenesis: where do we stand? Drug Resist Updat (2006) 1.08
Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin. Biochemistry (2004) 1.08
FTDP-17 mutations compromise the ability of tau to regulate microtubule dynamics in cells. J Biol Chem (2006) 1.08
A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence. Mol Cancer Ther (2005) 1.07
Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation. J Biol Chem (2011) 1.07
HIV-1 Tat protein enhances microtubule polymerization. Retrovirology (2005) 1.06
Model based dynamics analysis in live cell microtubule images. BMC Cell Biol (2007) 1.06
Radial compression of microtubules and the mechanism of action of taxol and associated proteins. Biophys J (2005) 1.06
Determination of the size and chemical nature of the stabilizing "cap" at microtubule ends using modulators of polymerization dynamics. Biochemistry (2002) 1.04
Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane. Carcinogenesis (2008) 1.03
Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res (2010) 1.03
The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther (2003) 1.03
2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol Cancer Ther (2006) 1.02
Preparation of microtubule protein and purified tubulin from bovine brain by cycles of assembly and disassembly and phosphocellulose chromatography. Methods Cell Biol (2010) 1.02
Antimitotic sulfonamides inhibit microtubule assembly dynamics and cancer cell proliferation. Biochemistry (2006) 1.01
Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett (2002) 1.01
ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells. Exp Cell Res (2006) 1.00